All News

Found 153 articles

• Aptinyx Appoints Ashish Khanna CFO and CBO

  2/13/2018

  Mr. Khanna has served as chief business officer of Aptinyx since the company's inception in 2015.

• 

  Aptinyx Bags $70M Financing to Fuel Expanding Pipeline

  12/18/2017

  The round was led by Bain Capital Life Sciences.

• Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder

  12/7/2017

  The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.

• Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as CCO

  12/7/2017

  Andy's experience will be instrumental in achieving and leveraging anticipated milestones,.

• Eton Pharma Appoints Dr. Norbert Riedel To Its Board Of Directors

  9/8/2017

• Aptinyx Initiates Phase II Clinical Studies Evaluating NYX-2925 In Two Chronic Pain Conditions

  8/1/2017

• Aptinyx Chief Scientific Officer Joseph Moskal, Ph.D. Named Fellow By National Academy Of Inventors And The American Institute For Medical And Biological Engineering

  2/21/2017

• Aptinyx Awarded Up To $2.85 Million In NIH Grants To Research NMDA Receptor Modulation For The Treatment Of Neuropathic Pain And Age-Related Cognitive Decline

  11/11/2016

• Aptinyx Receives FDA Fast Track Designation For Development Of NYX-2925 As Treatment For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

  9/13/2016

• Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925

  7/13/2016

• Naurex Spinout Aptinyx Banks $65 Million Series A to Advance Therapies for Neurological Disorders

  5/10/2016

• Zytoprotec GmbH Appoints Joerg Vienken And Norbert Riedel To Supervisory Board

  3/30/2016

• After Allergan Acquisition, Naurex Spins Out New Brain Research Company, Aptinyx

  9/17/2015